Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, ...

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Market forces rained on the parade of Novavax, Inc. (NASDAQ:NVAX) shareholders today, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) forecasts ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has earned an average recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Novavax (NVAX) announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

Shares of Novavax Inc. NVAX advanced 5.97% to $8.34 Friday, on what proved to be an all-around positive trading session for ...

Shares of Novavax Inc. NVAX slid 3.18% to $7.92 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.18% to 17,436.10 ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...